Replies to post #156462 on Biotech Values

[genisi]

You are thinking of patients while GILD is thinking of making max profit.
I'm not even sure the 7% difference doesn't show stst-sig non inferiority to SOC and while I agree that the right way would be to separate GT2 and 3 and find a better combo for GT3, I think that in light of SOC, no options, no resistance, the FDA will approve.